Seeking Alpha

ThinkEquity initiates coverage on Seattle Genetics (SGEN +0.6% to $25.99) with a "buy" rating...

ThinkEquity initiates coverage on Seattle Genetics (SGEN +0.6% to $25.99) with a "buy" rating and a price target of $30, citing the opportunity for SGEN's Adcetris treatment for Hodgkin's lymphoma. ThinkEquity's move follows positive notes from Needham and Oppenheimer, but a downgrade from Piper Jaffray.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)